Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 1/20 | 0.41 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13036657 | 0.90 | CTSK (0.45) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL13956771 | 0.87 | CTSK (0.55) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL21509312 | 0.87 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL2721327 | 0.87 | CTSK (0.55) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL9727285 | 0.85 | CTSK (0.55) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL15290789 | 0.83 | CYP1A2 (0.45) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL28195152 | 0.81 | CTSK (0.52) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL23260554 | 0.80 | CTSK (0.57) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL13036653 | 0.80 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL12652419 | 0.79 | CTSK (0.56) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829548-B2 | Compounds useful in the treatment of HIV | MEDIVIR AB (SE) | 2010-11-09 | — | — | US | disclosed |
| US-7829548-B2 | Compounds useful in the treatment of HIV | MEDIVIR AB (SE) | 2010-11-09 | — | — | US | disclosed |
| EP-1835916-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF HIV | MEDIVIR AB (SE) | 2009-04-01 | — | — | EP | disclosed |
| US-20080176817-A1 | Compounds Useful in the Treatment of Hiv | MEDIVIR AB (SE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176817-A1 | Compounds Useful in the Treatment of Hiv | MEDIVIR AB (SE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176817-A1 | Compounds Useful in the Treatment of Hiv | MTAP, NUDT1, TYMP | CTSK 3127/4885CTSS 1946/4885CA1 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.